Serving science company Thermo Fisher Scientific revealed on Tuesday the launch of the new AcroMetrix Coronavirus 2019 (COVID-19) RNA Control product to monitor and validate COVID-19 molecular diagnostic tests.
The company has designed and developed this control as a synthetic RNA, non-infectious control to help labs validate and monitor COVID-19 molecular diagnostic tests at two different concentrations: a low positive control and an ultra-low positive control under FDA guidelines.
AcroMetrix Coronavirus 2019 (COVID-19) RNA Control is prepared by formulating synthetic RNA transcripts with highly unique N, S, E and Orf1ab regions of SARS-CoV-2 genome into proprietary buffer. The kit contains two vials of SARS-CoV-2 specific RNA that will result low positive and ultra-low positive in used Polymerase Chain Reaction (PCR) based Coronavirus 2019 nucleic acid testing methods.
Additionally, the company's online resource has up-to-date information about its response to the COVID-19 pandemic, including availability of diagnostic test kits. The COVID-19 RNA Control is available as a Research Use Only (RUO) product and is not intended for clinical use.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial